Agios Pharmaceuticals, Inc. (AGIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Agios Pharmaceuticals reported revenue of $54.0M, up 48.0% from $36.5M the year before. Net income was -$412.8M (a -764.0% net margin), or -$7.12 per diluted share. Gross margin was 88.3% and operating margin was -873.9%. Operating activities generated -$373.0M of cash, leaving -$377.3M of free cash flow. At fiscal year end, Agios Pharmaceuticals held $1.30B in total assets against $104.1M in total liabilities, including $89.1M of cash and equivalents.
Open the full interactive Agios Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Agios Pharmaceuticals Key Stats
| Share Price | $30.21 |
|---|---|
| Market Cap | $1.80B |
| Revenue YoY Growth | +48.0% |
| 52-Week Range | $22.34 – $45.49 |
| Shares Outstanding | 59.5 million (basic, 2026 Q2) |
Agios Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $203.2M | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Cost of Goods Sold | $2.8M | — | $1.7M | $2.9M | $4.2M | $6.3M |
| Gross Profit | $200.4M | — | $12.5M | $23.9M | $32.3M | $47.7M |
| Operating Income | -$316.1M | -$378.4M | -$389.0M | -$391.5M | -$425.7M | -$472.1M |
| Pre-Tax Income | -$327.4M | -$356.5M | -$231.8M | -$352.1M | $718.0M | -$413.8M |
| Income Tax | -$79,000 | -$1.96B | — | — | $44.2M | -$1.0M |
| Net Income | -$327.4M | $1.60B | -$231.8M | -$352.1M | $673.7M | -$412.8M |
| Diluted EPS | -$4.74 | $26.55 | -$4.23 | -$6.33 | $11.64 | -$7.12 |
Agios Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $12.9M | $20.0M | $20.7M | $44.7M |
| Net Income | -$103.4M | -$108.0M | -$99.1M | -$100.7M |
| Diluted EPS | -$1.78 | -$1.86 | -$1.69 | -$1.69 |
Agios Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $127.4M | $203.1M | $139.3M | $88.2M | $76.2M | $89.1M |
| Current Assets | $636.7M | $1.06B | $832.8M | $833.8M | $965.6M | $942.1M |
| Total Assets | $853.0M | $1.44B | $1.24B | $937.1M | $1.66B | $1.30B |
| Current Liabilities | $94.4M | $59.8M | $62.6M | $68.0M | $81.2M | $82.2M |
| Total Liabilities | $453.5M | $145.8M | $137.9M | $126.1M | $122.2M | $104.1M |
| Shareholders' Equity | $399.5M | $1.29B | $1.10B | $811.0M | $1.54B | $1.19B |
Agios Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$290.8M | -$407.3M | -$309.5M | -$296.1M | -$389.8M | -$373.0M |
| Cash From Investing | $75.7M | $1.25B | $243.3M | $239.6M | $363.4M | $377.2M |
| Cash From Financing | $261.5M | -$765.8M | $2.4M | $5.4M | $14.4M | $8.7M |
| Free Cash Flow | -$305.7M | -$413.1M | -$314.4M | -$297.1M | -$391.5M | -$377.3M |
Figures from Agios Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Agios Pharmaceuticals financials page for every line item.
Agios Pharmaceuticals Company Profile
| Ticker | AGIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001439222 |
Frequently Asked Questions
What was Agios Pharmaceuticals' revenue in fiscal 2025?
Agios Pharmaceuticals (AGIO) reported revenue of $54.0M for fiscal 2025.
What is Agios Pharmaceuticals' annual revenue history?
Agios Pharmaceuticals' annual revenue by fiscal year: 2020: $203.2M; 2021: $0; 2022: $14.2M; 2023: $26.8M; 2024: $36.5M; 2025: $54.0M.
What was Agios Pharmaceuticals' net income in fiscal 2025?
Agios Pharmaceuticals reported net income of -$412.8M for fiscal 2025.
What was Agios Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Agios Pharmaceuticals' diluted EPS was -$7.12 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Agios Pharmaceuticals generate in fiscal 2025?
Agios Pharmaceuticals generated -$377.3M of free cash flow in fiscal 2025.
What was Agios Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Agios Pharmaceuticals reported revenue of $44.7M.
How many shares of Agios Pharmaceuticals are outstanding?
Agios Pharmaceuticals reported a weighted average of 59.5 million basic shares outstanding in 2026 Q2.
What is Agios Pharmaceuticals' market cap?
Based on its latest closing price, Agios Pharmaceuticals (AGIO) has a market capitalization of about $1.80B.
When does Agios Pharmaceuticals' fiscal year end?
Agios Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Agios Pharmaceuticals headquartered?
Agios Pharmaceuticals lists its business address in Cambridge, Massachusetts in its SEC filings.